scispace - formally typeset
B

Bo Lu

Researcher at Ohio State University

Publications -  390
Citations -  24905

Bo Lu is an academic researcher from Ohio State University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 58, co-authored 353 publications receiving 21823 citations. Previous affiliations of Bo Lu include Wuhan University of Technology & Wuhan University.

Papers
More filters
Journal ArticleDOI

Porphyrin and Galactosyl Conjugated Micelles for Targeting Photodynamic Therapy

TL;DR: The results indicated that porphyrin and galactosyl conjugated polymer micelles exhibited higher targeting and photodynamic therapy efficacy in HepG2 cells than in HEp2 cells.
Journal ArticleDOI

When Did Decapods Invade Hydrothermal Vents? Clues from the Western Pacific and Indian Oceans

TL;DR: This study investigated seven representative decapod species from four hydrothermal vents throughout the Western Pacific and Indian Oceans and found that continental-derived property of the West Pacific province is compatible with the possibility that vent decapods diversified from ancestors from shallow-water regions such as cold seeps.
Journal ArticleDOI

M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated Lung cancer models

TL;DR: M867 has the potential to prolong tumor growth delay by inhibiting tumor proliferation and enhances the cytotoxic effects of radiation on lung cancer and its vasculature both in vitro and in vivo.
Journal ArticleDOI

Optimal Pair Matching With Two Control Groups

TL;DR: In this article, the problem of optimal pair matching with two control groups is shown by a series of transformations to be equivalent to a particular form of optimal nonbipartite matching, a problem for which polynomial time algorithms exist.
Journal ArticleDOI

ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non–Small Cell Lung Cancer Expressing EML4-ALK

TL;DR: Findings indicate that PF02341066 acts as a radiation sensitizer in cells harboring the EML4-ALK fusion, providing a rationale for a clinical trial combining ALK inhibitor with radiation in the NSCLCs expressing ALK.